AVEO AVEO Pharmaceuticals Inc

On January 5, 2023, AVEO Pharmaceuticals, Inc. (the “Company”) held a special meeting of the stockholders of the Company (the “Special Meeting”). At the Special Meeting, the stockholders of the Company voted on the proposals set forth below, which were set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 25, 2022, as supplemented on December 23, 2022. The final voting results for each proposal are set forth below. As of the close of business on November 18, 2022, the record date of the Special Meeting, there were 34,763,127 shares of common stock of the Company, par value $0.001 per share (“Company Common Stock”), outstanding, each of which was entitled to one vote on each proposal at the Special Meeting. At the Special Meeting, a total of 21,241,190 shares of Company Common Stock, representing approximately 61.1% of the outstanding shares of Company Common Stock entitled to vote, were present in person or represented by proxy, constituting a quorum to conduct business.

Proposal No. 1 – The Merger Proposal: To consider and vote on a proposal to adopt the Agreement and Plan of Merger, dated as of October 18, 2022, among LG Chem, Ltd., a corporation organized and existing under the laws of the Republic of Korea (“LG Chem”), Acacia Acquisition Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of LG Chem (“Merger Sub”), and the Company, pursuant to which Merger Sub will be merged with and into the Company, with the Company surviving the merger as an indirect wholly owned subsidiary of LG Chem (the “Merger,” and such proposal, the “Merger Proposal”)

The Merger Proposal was approved by the requisite vote of the Company’s stockholders.

Proposal No. 2 – The Merger Compensation Proposal: To consider and vote on a proposal to approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to the Company’s named executive officers that is based on or otherwise relates to the Merger (the “Merger Compensation Proposal”).

The Merger Compensation Proposal was approved by the requisite vote of the Company’s stockholders.

Proposal No. 3 – The Adjournment Proposal: To consider and vote on a proposal to approve the adjournment of the special meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes to approve the Merger Proposal at the time of the Special Meeting (the “Adjournment Proposal”)

The Adjournment Proposal was approved by the requisite vote of the Company’s stockholders. However, adjournment of the Special Meeting was deemed not necessary because there was a quorum present and there were sufficient proxies at the time of the Special Meeting to approve the Merger Proposal.